Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 245

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Recommendations for Management of Liver and Biliary Tract Disease in Cystic Fibrosis

Sokol, Ronald J., Durie, Peter R.·1999·Journal of Pediatric Gastroenterology & Nutrition

Abstract

Although involvement of the liver and biliary tract has been recognized as a complication of cystic fibrosis (CF) since Anderson's initial description of CF in 1938 (1), the clinical significance of hepatobiliary disease in CF has not been well characterized until recently. The clinically silent development of liver complications has often been eclipsed by the obvious manifestations of pulmonary and pancreatic abnormalities. Because of improved life expectancy in the past 2 decades, now reported to be 31 years, liver disease has assumed greater importance to patients with CF and those involved in their care. Unfortunately, clinical identification of liver disease in CF has been difficult and inaccurate because of the general absence of symptoms of the developing fibrotic liver lesion. Thus, early diagnosis and therapeutic intervention has not been possible. In recent years, advances in our understanding of the function of the cystic fibrosis transmembrane conductance regulator (CFTR) in bile duct epithelia and of the mechanisms of fibrogenesis in the liver have provided a stronger scientific basis for the pathogenesis of disease, leading to insights concerning potentially novel therapeutic approaches. For these reasons, the Cystic Fibrosis Foundation has recognized the need to revise the previous Recommendations for Management of Liver and Biliary Tract Disease in Cystic Fibrosis, published in 1989, to reflect the new scientific advances and clinical information in this area. Basic Defect in Biliary Epithelium The cftr gene in the normal human liver is expressed in the epithelia of the intrahepatic and extrahepatic bile ducts and the gallbladder, and the CFTR protein is localized to the apical domain of these cells (2). CFTR is not expressed in hepatocytes or other cells of the liver (2). It is therefore probable that CFTR is involved in chloride and water secretion into bile at the ductal level (3). CFTR gene mutations cause reduced, dysfunctional, or absent cyclic adenosine monophosphate-inducible chloride channel function in bile duct epithelia (3); thus, impaired or abolished CFTR-induced chloride efflux across these cells appears to result in concomitant reduction in water and sodium movement into bile. It is also possible that CFTR regulates other ion channels in bile duct epithelia. The role of CFTR, relative to that of other chloride channels, in increasing bile flow and diluting biliary fluid remains to be determined. However, CFTR mutations most certainly cause abnormalities in the composition, consistency, alkalinity or flow of bile which, in turn, contribute to the pathogenesis of the liver lesions observed in CF. Although specific gene mutations (genotypes) have been associated with the severity of pancreatic involvement in CF, there is no correlation between the frequency of occurrence of the cftr mutation or genotype and clinically detectable liver disease in patients with CF (4-6). However, there appears to be a lower frequency of liver disease in pancreatic-sufficient patients with CF (7,8). Because all patients with CF have abnormal CFTR in the biliary tree, it is unclear why significant liver disease does not develop in all patients. In fact, most patients with CF do not show clinical symptoms or signs of liver disease, despite the probable presence (based on autopsy series) of focal biliary cirrhosis in most older patients. This variable onset and severity of liver disease suggests that there are other modifying genetic or environmental factors that determine whether hepatobiliary involvement will be of clinical significance in a given case. In this regard, Duthie et al. (9) found that the HLA haplotype B7-DR15-DQ6 was associated with an increased risk of chronic liver disease in male patients with CF, implicating a possible immune pathogenesis of hepatobiliary injury in addition to the CFTR defect. It should be pointed out that, as the median survival improves in CF, a longer time is available for the progression of portal fibrosis and cirrhosis; thus, complications of liver disease and portal hypertension may become more common. Pathogenesis of Hepatobiliary Injury in Cystic Fibrosis A spectrum of hepatobiliary lesions is observed in CF (Table 1). The most important clinically is the development of biliary obstruction and periportal fibrosis. The mechanism causing these liver lesions in CF has been attributed to focal inspissation of biliary secretions in intrahepatic bile ducts, leading gradually to the development of portal fibrosis, bridging and, eventually, cirrhosis (Figure 1). Factors that contribute to the abnormal viscosity, decreased flow, and increased concentration of components of bile in CF may be defective chloride transport, sodium reabsorption, and bile dilution in intrahepatic bile ducts; impaired secretion of mucins and other protective proteins from submucosal glands; or increased glycine-conjugated bile acids. Altered bile composition or decreased bile flow causes o

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00005176-199900001-00001

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 245

Metadata

Authors
Sokol, R. J., & Durie, P. R.
Venue
Journal of Pediatric Gastroenterology & Nutrition
Publisher
Wiley
Published
1999
Volume
28
Pages
S1-S13
ISSN
0277-2116 (ISSN-L)
OpenAlex
W2030747774
Cited by
245
References
2
FWCI
7.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recommendations for Management of Liver and Biliary Tract Disease in Cystic Fibrosis. https://app.cochat.ai/papers/10.1097/00005176-199900001-00001
The paper
Sokol, R. J., & Durie, P. R. (1999). Recommendations for Management of Liver and Biliary Tract Disease in Cystic Fibrosis. Journal of Pediatric Gastroenterology & Nutrition. https://doi.org/10.1097/00005176-199900001-00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.